Liraglutide Administration Guidelines for Type 2 Diabetes Management

Introduction to Liraglutide Administration

• The American College of Cardiology and American Diabetes Association recommend liraglutide to be administered once daily, not once weekly, for effective type 2 diabetes management 1, 2

Dosing Protocol

• The American College of Cardiology and American Diabetes Association specify the following dosing protocol for liraglutide: initial dose of 0.6 mg subcutaneously once daily, titration to 1.2 mg once daily after at least 1 week, and maximum dose of 1.8 mg once daily if needed for glycemic control 1, 2

Pharmacokinetic Profile and Administration Frequency

• Liraglutide's pharmacokinetic profile is designed for once-daily administration, and using it once weekly would result in inadequate drug levels, poor glycemic control, and failure to achieve therapeutic outcomes 1, 2

Comparison of GLP-1 Receptor Agonists

• The administration frequency of different GLP-1 receptor agonists, including liraglutide, semaglutide, dulaglutide, exenatide extended-release, and lixisenatide, varies, with liraglutide requiring once-daily administration 1, 2

Patient Instruction and Potential Consequences of Incorrect Administration

• Patients should be instructed to inject liraglutide once daily at approximately the same time each day, starting at 0.6 mg daily for one week, and gradually increasing to 1.2 mg and potentially 1.8 mg as needed and tolerated 1, 2
• Using liraglutide once weekly instead of daily would result in suboptimal glycemic control, potentially increase the risk of diabetes complications, and compromise cardiovascular and renal protective effects 1, 2

Common Mistakes to Avoid

• Confusing liraglutide with weekly GLP-1 RAs like semaglutide or dulaglutide, inadequate titration, discontinuation due to early side effects, and inappropriate expectations should be avoided to ensure optimal results 1, 2